BridgeBio Pharma
BBIO
253 hedge funds and large institutions have $4.39B invested in BridgeBio Pharma in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 107 increasing their positions, 74 reducing their positions, and 34 closing their positions.
317% more call options, than puts
Call options by funds: $288M | Put options by funds: $68.9M
45% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 74
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
1% more funds holding
Funds holding: 251 → 253 (+2)
1% less capital invested
Capital invested by funds: $4.43B → $4.39B (-$38.7M)
1.72% less ownership
Funds ownership: 93.5% → 91.78% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$45.9M |
| 2 |
JP Morgan Chase
New York
|
+$27.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$21.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$152M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$36.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$30.8M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$27.6M |
| 5 |
Man Group
London,
United Kingdom
|
-$15.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DC
276
Davenport & Co
Richmond,
Virginia
| – | -$258K | -10,200 | Closed |
|
|
FBT
277
First Bank & Trust
Brookings,
South Dakota
| – | -$204K | -8,044 | Closed |
|
|
CL
278
CSS LLC
Chicago,
Illinois
| – | -$164K | -6,481 | Closed |
|
279
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$114K | -4,500 | Closed |
|
280
Lazard Asset Management
New York
| – | -$102K | -3,867 | -99% |
|
|
HT
281
Headlands Technologies
Chicago,
Illinois
| – | -$48.3K | -1,905 | Closed |
|
282
Pacer Advisors
Malvern,
Pennsylvania
| – | -$39.1K | -1,545 | Closed |
|
|
IUHSA
283
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| – | -$3.88K | -153 | Closed |
|
|
IC
284
Innealta Capital
Austin,
Texas
| – | -$1.72K | -68 | Closed |
|
|
AAP
285
Arax Advisory Partners
Denver,
Colorado
| – | -$1.29K | -51 | Closed |
|
|
CAM
286
Creekmur Asset Management
Morton,
Illinois
| – | -$76 | -3 | Closed |
|
|
HWM
287
Hemington Wealth Management
Falls Church,
Virginia
| – | +$919 | +35 | New |
|
BBIO Hedge Fund Activity: Q3 2024 in Review
253 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2024, worth a combined $4.39B — down 0.87% from $4.43B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new BBIO positions and 34 closed out — a net gain of 4 holders — while 107 added to existing stakes and 74 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $45.9M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $152M.
- 253 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2024, up from 251 in Q2 2024.
- Funds reported $4.39B of BridgeBio Pharma stock for Q3 2024, down 0.87% quarter-over-quarter.
- 38 funds opened new BridgeBio Pharma positions in Q3 2024 and 34 closed out, a net change of +4 holders.
- The largest BridgeBio Pharma buyer in Q3 2024 was Farallon Capital Management, an estimated $45.9M added.
- The largest BridgeBio Pharma seller in Q3 2024 was Kohlberg Kravis Roberts & Co, an estimated $152M sold.
Based on aggregated 13F filings for Q3 2024.